Company intelligence / Profile preview

Archer Biosciences

New York, New York, United Statesarcherpharmaceuticals.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Archer Biosciences, Inc. was a biotech company that developed TPI-287 (an abeotaxane) for metastatic melanoma. As of July, the company had initiated dosing in the third cohort of a clinical trial to determine safety and maximum tolerated dose of TPI-287 in combination with temozolomide for adult patients with metastatic melanoma, including those with brain metastases. The drug demonstrated preclinical ability to cross the blood-brain barrier and avoid multidrug resistance efflux pumps[4]. No recent activity or evidence of ongoing operations is available.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

nilvadipine

Phase 2

Indications: Alzheimer's disease

Beyond the preview

Go deeper on Archer Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Archer Biosciences.

Explore the full profile